Identification

Name
Isocarboxazid
Accession Number
DB01247  (APRD00701)
Type
Small Molecule
Groups
Approved
Description

Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor.[2] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.[4] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.

Structure
Thumb
Synonyms
  • Isocarboxazida
  • Isocarboxazide
  • Isocarboxazidum
External IDs
RO 5-0831 / RO-5-0831
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MarplanTablet10 mg/1OralValidus Pharmaceuticals1959-07-01Not applicableUs
International/Other Brands
Enerzer (Takeda) / Isocarboxazid (Alliance) / Marplan (Validus Pharm)
Categories
UNII
34237V843T
CAS number
59-63-2
Weight
Average: 231.2505
Monoisotopic: 231.100776675
Chemical Formula
C12H13N3O2
InChI Key
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
InChI
InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
IUPAC Name
N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
SMILES
CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1

Pharmacology

Indication

Isocarboxazid is indicated for the treatment of the enduring and debilitating symptoms of depression that have not responded to other antidepressant drugs.[7] Depression is a common but serious mood disorder. The patient will present changes in its feelings, thoughts, and ability to handle everyday activities. For a mood disorder to be considered as depression, the symptoms should be present for at least two weeks.[8]

Associated Conditions
Pharmacodynamics

In vivo and in vitro studies demonstrated isocarboxazid-driven inhibition of MAO in the brain, heart, and liver. The reduced MAO activity, caused by isocarboxazid, results in an increased concentration of serotonin, epinephrine, norepinephrine, and dopamine in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. The increase of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors like isocarboxazid.[1]

Mechanism of action

Isocarboxazid works by irreversibly blocking the action of monoamine oxidases (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B).[1] Isocarboxacid, like other monoamine oxidase inhibitors, are unique psychopharmacological agents whose clinical effect is related to the direct action of the monoamine oxidases to transform them into reactive metabolites.[5]

TargetActionsOrganism
AAmine oxidase [flavin-containing] A
inhibitor
Human
AAmine oxidase [flavin-containing] B
inhibitor
Human
Absorption

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are readily absorbed by the GI tract, present a low bioavailability and reach peak concentrations in 1-2 hours.[5]

Volume of distribution
Not Available
Protein binding

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs present a very high protein binding percentage.[5]

Metabolism

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are rapidly metabolized by acetylation in the liver.[5] As part of the metabolism, hippuric acid is a major metabolite.[6]

Route of elimination

Most of the eliminated dose is found in the urine, accounting for the 42.5% of the administered dose after 24 hours. From this amount, 75% of the renally eliminated drug is in the form of hippuric acid. Another section of the eliminated dose is observed through the intestinal tract and it accounts for 22% of the administered dose after 24 hours.[3]

Half life

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor.[6] These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.[5]

Clearance
Not Available
Toxicity

Long-term toxicity studies to evaluate the carcinogenic, mutagenic and fertility impairment potential have not been conducted.[Label]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineIsocarboxazid may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Isocarboxazid.Experimental
3,4-MethylenedioxyamphetamineThe therapeutic efficacy of 3,4-Methylenedioxyamphetamine can be increased when used in combination with Isocarboxazid.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe therapeutic efficacy of 4-Bromo-2,5-dimethoxyamphetamine can be increased when used in combination with Isocarboxazid.Experimental, Illicit
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be increased when used in combination with Isocarboxazid.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Isocarboxazid.Experimental, Illicit
7-NitroindazoleThe therapeutic efficacy of 7-Nitroindazole can be increased when used in combination with Isocarboxazid.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineIsocarboxazid may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Abediterol.Investigational
AcarboseIsocarboxazid may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololIsocarboxazid may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcepromazineThe therapeutic efficacy of Acepromazine can be increased when used in combination with Isocarboxazid.Approved, Vet Approved
AceprometazineThe therapeutic efficacy of Aceprometazine can be increased when used in combination with Isocarboxazid.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Acetophenazine.Approved
AdinazolamThe therapeutic efficacy of Adinazolam can be increased when used in combination with Isocarboxazid.Approved
AdipiplonThe therapeutic efficacy of Adipiplon can be increased when used in combination with Isocarboxazid.Investigational
AlaproclateThe therapeutic efficacy of Alaproclate can be increased when used in combination with Isocarboxazid.Experimental
AlbiglutideIsocarboxazid may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aldesleukin.Approved
AlfentanilIsocarboxazid may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Alfentanil.Approved, Illicit
AliskirenIsocarboxazid may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Isocarboxazid.Approved, Investigational
AlogliptinIsocarboxazid may increase the hypoglycemic activities of Alogliptin.Approved
AlosetronAlosetron may increase the serotonergic activities of Isocarboxazid.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Isocarboxazid.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Isocarboxazid.Illicit
AlprazolamThe therapeutic efficacy of Alprazolam can be increased when used in combination with Isocarboxazid.Approved, Illicit, Investigational
AlprenololIsocarboxazid may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Isocarboxazid.Approved
AmbrisentanIsocarboxazid may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Isocarboxazid.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amiloride.Approved
AmineptineThe therapeutic efficacy of Amineptine can be increased when used in combination with Isocarboxazid.Illicit, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Isocarboxazid.Approved, Investigational
AmisulprideThe therapeutic efficacy of Amisulpride can be increased when used in combination with Isocarboxazid.Approved, Investigational
AmitriptylineThe therapeutic efficacy of Amitriptyline can be increased when used in combination with Isocarboxazid.Approved
AmitriptylinoxideIsocarboxazid may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineIsocarboxazid may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Isocarboxazid.Approved, Illicit
AmoxapineThe therapeutic efficacy of Amoxapine can be increased when used in combination with Isocarboxazid.Approved
AmperozideThe therapeutic efficacy of Amperozide can be increased when used in combination with Isocarboxazid.Experimental
AmphetamineIsocarboxazid may increase the hypertensive activities of Amphetamine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isocarboxazid.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amyl Nitrite.Approved
AniracetamThe therapeutic efficacy of Aniracetam can be increased when used in combination with Isocarboxazid.Experimental
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Isocarboxazid.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Arformoterol.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Aripiprazole can be increased when used in combination with Isocarboxazid.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isocarboxazid.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Isocarboxazid.Approved, Investigational
AsenapineThe therapeutic efficacy of Asenapine can be increased when used in combination with Isocarboxazid.Approved
AtenololIsocarboxazid may increase the hypotensive activities of Atenolol.Approved
AtomoxetineIsocarboxazid may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineIsocarboxazid may increase the hypertensive activities of Atropine.Approved, Vet Approved
AzaperoneThe therapeutic efficacy of Azaperone can be increased when used in combination with Isocarboxazid.Investigational, Vet Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Azilsartan medoxomil.Approved, Investigational
BambuterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Isocarboxazid.Experimental
BarbitalBarbital may increase the hypotensive activities of Isocarboxazid.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Isocarboxazid.Approved
BenactyzineThe therapeutic efficacy of Benactyzine can be increased when used in combination with Isocarboxazid.Withdrawn
BenazeprilIsocarboxazid may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideIsocarboxazid may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinIsocarboxazid may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe therapeutic efficacy of Benperidol can be increased when used in combination with Isocarboxazid.Approved, Investigational
BenzphetamineIsocarboxazid may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilIsocarboxazid may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Isocarboxazid.Approved, Investigational
BetaxololIsocarboxazid may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineIsocarboxazid may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bezafibrate.Approved, Investigational
BietaserpineIsocarboxazid may increase the hypotensive activities of Bietaserpine.Experimental
BifemelaneThe therapeutic efficacy of Bifemelane can be increased when used in combination with Isocarboxazid.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bifeprunox.Investigational
BimatoprostIsocarboxazid may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololIsocarboxazid may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bitolterol.Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Isocarboxazid.Approved, Investigational
BosentanIsocarboxazid may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Isocarboxazid may increase the hypotensive activities of BQ-123.Investigational
BretyliumIsocarboxazid may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Isocarboxazid.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Brimonidine.Approved
BrofaromineIsocarboxazid may increase the hypertensive activities of Brofaromine.Experimental
BromazepamThe therapeutic efficacy of Bromazepam can be increased when used in combination with Isocarboxazid.Approved, Illicit, Investigational
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Isocarboxazid.Approved, Investigational
BromperidolThe therapeutic efficacy of Bromperidol can be increased when used in combination with Isocarboxazid.Approved, Investigational
BufotenineThe therapeutic efficacy of Bufotenine can be increased when used in combination with Isocarboxazid.Experimental, Illicit
BumetanideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Isocarboxazid.Approved, Investigational
BupranololIsocarboxazid may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Isocarboxazid.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bupropion.Approved
BupropionThe therapeutic efficacy of Bupropion can be increased when used in combination with Isocarboxazid.Approved
BuspironeThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Buspirone.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Butaperazine.Experimental
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Isocarboxazid.Approved, Illicit, Vet Approved
ButriptylineIsocarboxazid may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Isocarboxazid.Approved
CadralazineIsocarboxazid may increase the hypotensive activities of Cadralazine.Experimental
CafedrineIsocarboxazid may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinIsocarboxazid may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanIsocarboxazid may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilIsocarboxazid may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilIsocarboxazid may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilIsocarboxazid may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Isocarboxazid.Approved, Investigational
CarbamazepineThe therapeutic efficacy of Carbamazepine can be increased when used in combination with Isocarboxazid.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isocarboxazid.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Isocarboxazid.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Isocarboxazid.Approved, Investigational
CaroxazoneIsocarboxazid may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololIsocarboxazid may increase the hypotensive activities of Carteolol.Approved
CarvedilolIsocarboxazid may increase the hypotensive activities of Carvedilol.Approved, Investigational
CathinoneThe therapeutic efficacy of Cathinone can be increased when used in combination with Isocarboxazid.Illicit
CeliprololIsocarboxazid may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlordiazepoxideThe therapeutic efficacy of Chlordiazepoxide can be increased when used in combination with Isocarboxazid.Approved, Illicit, Investigational
ChlormezanoneThe therapeutic efficacy of Chlormezanone can be increased when used in combination with Isocarboxazid.Approved, Investigational, Withdrawn
ChlorothiazideIsocarboxazid may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineIsocarboxazid may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorproethazine.Experimental
ChlorpromazineThe therapeutic efficacy of Chlorpromazine can be increased when used in combination with Isocarboxazid.Approved, Investigational, Vet Approved
ChlorpropamideIsocarboxazid may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe therapeutic efficacy of Chlorprothixene can be increased when used in combination with Isocarboxazid.Approved, Investigational, Withdrawn
ChlorthalidoneIsocarboxazid may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineIsocarboxazid may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilIsocarboxazid may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Isocarboxazid.Approved, Investigational
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Isocarboxazid.Approved, Investigational
CirazolineIsocarboxazid may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe therapeutic efficacy of Citalopram can be increased when used in combination with Isocarboxazid.Approved
ClemastineIsocarboxazid may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Isocarboxazid.Approved, Investigational
ClomipramineThe therapeutic efficacy of Clomipramine can be increased when used in combination with Isocarboxazid.Approved, Investigational, Vet Approved
ClonidineIsocarboxazid may increase the hypertensive activities of Clonidine.Approved
ClopenthixolThe therapeutic efficacy of Clopenthixol can be increased when used in combination with Isocarboxazid.Experimental
CloranololIsocarboxazid may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe therapeutic efficacy of Clorazepate can be increased when used in combination with Isocarboxazid.Approved, Illicit
ClothiapineThe therapeutic efficacy of Clothiapine can be increased when used in combination with Isocarboxazid.Experimental
ClozapineThe therapeutic efficacy of Clozapine can be increased when used in combination with Isocarboxazid.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Isocarboxazid.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Isocarboxazid.Approved, Investigational
CryptenamineIsocarboxazid may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Isocarboxazid.Approved
CyclopenthiazideIsocarboxazid may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideIsocarboxazid may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineIsocarboxazid may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinIsocarboxazid may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Isocarboxazid.Investigational
DeanolThe therapeutic efficacy of Deanol can be increased when used in combination with Isocarboxazid.Experimental
DebrisoquinIsocarboxazid may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilIsocarboxazid may increase the hypotensive activities of Delapril.Investigational
DeramciclaneThe therapeutic efficacy of Deramciclane can be increased when used in combination with Isocarboxazid.Investigational
DeserpidineIsocarboxazid may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Isocarboxazid.Approved
DesipramineThe therapeutic efficacy of Desipramine can be increased when used in combination with Isocarboxazid.Approved, Investigational
DesvenlafaxineThe therapeutic efficacy of Desvenlafaxine can be increased when used in combination with Isocarboxazid.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Deutetrabenazine.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateIsocarboxazid may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DextofisopamThe therapeutic efficacy of Dextofisopam can be increased when used in combination with Isocarboxazid.Investigational
DextroamphetamineIsocarboxazid may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanIsocarboxazid may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Isocarboxazid.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Isocarboxazid.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Isocarboxazid.Approved, Investigational
DiazepamThe therapeutic efficacy of Diazepam can be increased when used in combination with Isocarboxazid.Approved, Illicit, Investigational, Vet Approved
DiazoxideIsocarboxazid may increase the hypotensive activities of Diazoxide.Approved
DibenzepinThe therapeutic efficacy of Dibenzepin can be increased when used in combination with Isocarboxazid.Experimental
DiclofenamideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineIsocarboxazid may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionIsocarboxazid may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineIsocarboxazid may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Isocarboxazid.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Isocarboxazid.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Isocarboxazid.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Isocarboxazid.Experimental, Illicit
DiltiazemIsocarboxazid may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimetacrineIsocarboxazid may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe therapeutic efficacy of Dimethyltryptamine can be increased when used in combination with Isocarboxazid.Experimental, Illicit
DinutuximabThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dinutuximab.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Isocarboxazid.Approved, Illicit
DipivefrinIsocarboxazid may increase the hypertensive activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dipyridamole.Approved
DisopyramideIsocarboxazid may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Isocarboxazid is combined with Disulfiram.Approved
DixyrazineThe therapeutic efficacy of Dixyrazine can be increased when used in combination with Isocarboxazid.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Isocarboxazid.Approved, Investigational
DomperidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Domperidone.Approved, Investigational, Vet Approved
DoramectinThe therapeutic efficacy of Doramectin can be increased when used in combination with Isocarboxazid.Vet Approved
DorzolamideIsocarboxazid may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe therapeutic efficacy of Dosulepin can be increased when used in combination with Isocarboxazid.Approved
DoxapramIsocarboxazid may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinIsocarboxazid may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe therapeutic efficacy of Doxepin can be increased when used in combination with Isocarboxazid.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Doxofylline.Approved, Investigational
DoxylamineIsocarboxazid may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Isocarboxazid.Experimental
DronabinolThe therapeutic efficacy of Dronabinol can be increased when used in combination with Isocarboxazid.Approved, Illicit
DroperidolThe therapeutic efficacy of Droperidol can be increased when used in combination with Isocarboxazid.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Isocarboxazid.Experimental, Illicit
DroxidopaIsocarboxazid may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideIsocarboxazid may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe therapeutic efficacy of Duloxetine can be increased when used in combination with Isocarboxazid.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Isocarboxazid.Experimental, Illicit
EcopipamThe therapeutic efficacy of Ecopipam can be increased when used in combination with Isocarboxazid.Investigational
EfonidipineIsocarboxazid may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Isocarboxazid.Approved, Investigational
EmpagliflozinIsocarboxazid may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilIsocarboxazid may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatIsocarboxazid may increase the hypotensive activities of Enalaprilat.Approved
EndralazineIsocarboxazid may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Isocarboxazid.Approved, Investigational
EpanololIsocarboxazid may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineIsocarboxazid may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Eplerenone.Approved
EpoprostenolIsocarboxazid may increase the hypotensive activities of Epoprostenol.Approved
EprosartanIsocarboxazid may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Isocarboxazid.Approved
ErgonovineIsocarboxazid may increase the hypertensive activities of Ergonovine.Approved
ErgotamineIsocarboxazid may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe therapeutic efficacy of Escitalopram can be increased when used in combination with Isocarboxazid.Approved, Investigational
EsmirtazapineThe therapeutic efficacy of Esmirtazapine can be increased when used in combination with Isocarboxazid.Investigational
EsmololThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Esmolol.Approved
EstazolamThe therapeutic efficacy of Estazolam can be increased when used in combination with Isocarboxazid.Approved, Illicit
Etacrynic acidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Isocarboxazid.Approved
Ethyl loflazepateThe therapeutic efficacy of Ethyl loflazepate can be increased when used in combination with Isocarboxazid.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Isocarboxazid.Approved, Illicit
EtifoxineThe therapeutic efficacy of Etifoxine can be increased when used in combination with Isocarboxazid.Investigational, Withdrawn
EtizolamThe therapeutic efficacy of Etizolam can be increased when used in combination with Isocarboxazid.Approved
EtoperidoneIsocarboxazid may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Isocarboxazid.Illicit, Vet Approved
ExenatideIsocarboxazid may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineIsocarboxazid may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe therapeutic efficacy of Fencamfamine can be increased when used in combination with Isocarboxazid.Approved, Illicit, Withdrawn
FenfluramineIsocarboxazid may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamIsocarboxazid may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Isocarboxazid.Approved, Illicit, Investigational, Vet Approved
Ferulic acidIsocarboxazid may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isocarboxazid.Approved, Investigational
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Isocarboxazid.Approved, Investigational
FluanisoneThe therapeutic efficacy of Fluanisone can be increased when used in combination with Isocarboxazid.Experimental
FludiazepamThe therapeutic efficacy of Fludiazepam can be increased when used in combination with Isocarboxazid.Approved, Illicit
FlunitrazepamThe therapeutic efficacy of Flunitrazepam can be increased when used in combination with Isocarboxazid.Approved, Illicit
FluoxetineThe therapeutic efficacy of Fluoxetine can be increased when used in combination with Isocarboxazid.Approved, Vet Approved
FlupentixolThe therapeutic efficacy of Flupentixol can be increased when used in combination with Isocarboxazid.Approved, Investigational, Withdrawn
FluphenazineThe therapeutic efficacy of Fluphenazine can be increased when used in combination with Isocarboxazid.Approved
FlurazepamThe therapeutic efficacy of Flurazepam can be increased when used in combination with Isocarboxazid.Approved, Illicit, Investigational
FluspirileneThe therapeutic efficacy of Fluspirilene can be increased when used in combination with Isocarboxazid.Approved, Investigational
FluvoxamineThe therapeutic efficacy of Fluvoxamine can be increased when used in combination with Isocarboxazid.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Formoterol.Approved, Investigational
FosinoprilIsocarboxazid may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Isocarboxazid.Approved, Investigational
FurazolidoneIsocarboxazid may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Furosemide.Approved, Vet Approved
GabapentinThe therapeutic efficacy of Gabapentin can be increased when used in combination with Isocarboxazid.Approved, Investigational
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Isocarboxazid.Experimental
GepironeThe therapeutic efficacy of Gepirone can be increased when used in combination with Isocarboxazid.Investigational
GliclazideIsocarboxazid may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideIsocarboxazid may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideIsocarboxazid may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideIsocarboxazid may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Isocarboxazid.Approved, Investigational
GuanabenzIsocarboxazid may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelIsocarboxazid may increase the hypotensive activities of Guanadrel.Approved
GuanazodineIsocarboxazid may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineIsocarboxazid may increase the hypotensive activities of Guanethidine.Approved
GuanfacineIsocarboxazid may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorIsocarboxazid may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzIsocarboxazid may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanIsocarboxazid may increase the hypotensive activities of Guanoxan.Experimental
HalazepamThe therapeutic efficacy of Halazepam can be increased when used in combination with Isocarboxazid.Approved, Illicit, Withdrawn
HaloperidolThe therapeutic efficacy of Haloperidol can be increased when used in combination with Isocarboxazid.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Isocarboxazid.Approved, Vet Approved
HarmalineIsocarboxazid may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Isocarboxazid.Approved, Illicit, Investigational
HexamethoniumIsocarboxazid may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Isocarboxazid.Approved
HexoprenalineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineIsocarboxazid may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineIsocarboxazid may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideIsocarboxazid may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Isocarboxazid.Approved, Illicit
HydroflumethiazideIsocarboxazid may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Isocarboxazid.Approved, Illicit
HydroxyamphetamineIsocarboxazid may increase the hypertensive activities of Hydroxyamphetamine.Approved
HypericinThe therapeutic efficacy of Hypericin can be increased when used in combination with Isocarboxazid.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Isocarboxazid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Isocarboxazid.Investigational
ImipramineThe therapeutic efficacy of Imipramine can be increased when used in combination with Isocarboxazid.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Indacaterol.Approved
IndalpineThe therapeutic efficacy of Indalpine can be increased when used in combination with Isocarboxazid.Investigational, Withdrawn
IndapamideIsocarboxazid may increase the hypotensive activities of Indapamide.Approved
IndenololIsocarboxazid may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminIsocarboxazid may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartIsocarboxazid may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirIsocarboxazid may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineIsocarboxazid may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineIsocarboxazid may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanIsocarboxazid may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproIsocarboxazid may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Isocarboxazid.Approved
IprindoleThe therapeutic efficacy of Iprindole can be increased when used in combination with Isocarboxazid.Experimental
IproclozideIsocarboxazid may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidThe therapeutic efficacy of Iproniazid can be increased when used in combination with Isocarboxazid.Withdrawn
IrbesartanIsocarboxazid may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsoetarineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoflurane.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsocarboxazid may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinIsocarboxazid may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe therapeutic efficacy of Ketazolam can be increased when used in combination with Isocarboxazid.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Isocarboxazid.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Isocarboxazid.Approved, Nutraceutical, Withdrawn
LabetalolIsocarboxazid may increase the hypotensive activities of Labetalol.Approved
LacidipineIsocarboxazid may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lamotrigine.Approved, Investigational
LatanoprostIsocarboxazid may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineIsocarboxazid may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Levobupivacaine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Isocarboxazid.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Isocarboxazid.Approved, Investigational
LevomilnacipranThe therapeutic efficacy of Levomilnacipran can be increased when used in combination with Isocarboxazid.Approved, Investigational
LevonordefrinIsocarboxazid may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Isocarboxazid.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Levosimendan.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Linezolid.Approved, Investigational
LinsidomineIsocarboxazid may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideIsocarboxazid may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineIsocarboxazid may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilIsocarboxazid may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Isocarboxazid.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Isocarboxazid.Illicit
LofepramineThe therapeutic efficacy of Lofepramine can be increased when used in combination with Isocarboxazid.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Isocarboxazid.Approved, Investigational
LoprazolamThe therapeutic efficacy of Loprazolam can be increased when used in combination with Isocarboxazid.Experimental
LorazepamThe therapeutic efficacy of Lorazepam can be increased when used in combination with Isocarboxazid.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lorcaserin.Approved
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Isocarboxazid.Approved
LosartanIsocarboxazid may increase the hypotensive activities of Losartan.Approved
LoxapineThe therapeutic efficacy of Loxapine can be increased when used in combination with Isocarboxazid.Approved
LurasidoneThe therapeutic efficacy of Lurasidone can be increased when used in combination with Isocarboxazid.Approved, Investigational
Lysergic Acid DiethylamideThe therapeutic efficacy of Lysergic Acid Diethylamide can be increased when used in combination with Isocarboxazid.Illicit, Investigational, Withdrawn
MacitentanIsocarboxazid may increase the hypotensive activities of Macitentan.Approved
ManidipineIsocarboxazid may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Maprotiline.Approved, Investigational
MebanazineIsocarboxazid may increase the hypertensive activities of Mebanazine.Withdrawn
MebicarThe therapeutic efficacy of Mebicar can be increased when used in combination with Isocarboxazid.Experimental
MecamylamineIsocarboxazid may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminIsocarboxazid may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedazepamThe therapeutic efficacy of Medazepam can be increased when used in combination with Isocarboxazid.Experimental
MelitracenIsocarboxazid may increase the serotonergic activities of Melitracen.Experimental, Investigational
MelperoneThe therapeutic efficacy of Melperone can be increased when used in combination with Isocarboxazid.Approved, Investigational
MephedroneIsocarboxazid may increase the hypertensive activities of Mephedrone.Investigational
MephentermineIsocarboxazid may increase the hypertensive activities of Mephentermine.Approved
MeprobamateThe therapeutic efficacy of Meprobamate can be increased when used in combination with Isocarboxazid.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Isocarboxazid.Experimental
MequitazineIsocarboxazid may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe therapeutic efficacy of Mesoridazine can be increased when used in combination with Isocarboxazid.Approved, Investigational
MetaraminolIsocarboxazid may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminIsocarboxazid may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Isocarboxazid.Approved, Illicit
MethamphetamineIsocarboxazid may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Isocarboxazid.Approved
MethoserpidineIsocarboxazid may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe therapeutic efficacy of Methotrimeprazine can be increased when used in combination with Isocarboxazid.Approved, Investigational
MethoxamineIsocarboxazid may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Isocarboxazid.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of hypertension can be increased when Isocarboxazid is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Isocarboxazid.Experimental
Methylene blueIsocarboxazid may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateIsocarboxazid may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Isocarboxazid.Approved
MethysergideThe metabolism of Methysergide can be decreased when combined with Isocarboxazid.Approved
MetipranololIsocarboxazid may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Metoclopramide.Approved, Investigational
MetolazoneIsocarboxazid may increase the hypotensive activities of Metolazone.Approved
MetoprololIsocarboxazid may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineIsocarboxazid may increase the hypotensive activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mianserin.Approved, Investigational
MibefradilIsocarboxazid may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe therapeutic efficacy of Midazolam can be increased when used in combination with Isocarboxazid.Approved, Illicit
MidodrineIsocarboxazid may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe therapeutic efficacy of Midomafetamine can be increased when used in combination with Isocarboxazid.Experimental, Illicit, Investigational
MifepristoneIsocarboxazid may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolIsocarboxazid may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe therapeutic efficacy of Milnacipran can be increased when used in combination with Isocarboxazid.Approved, Investigational
MinaprineThe therapeutic efficacy of Minaprine can be increased when used in combination with Isocarboxazid.Approved
MinoxidilIsocarboxazid may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mirtazapine.Approved
MMDAIsocarboxazid may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Moclobemide.Approved, Investigational
MoexiprilIsocarboxazid may increase the hypotensive activities of Moexipril.Approved
MolindoneThe therapeutic efficacy of Molindone can be increased when used in combination with Isocarboxazid.Approved
MoperoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Moperone.Experimental
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Isocarboxazid.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Mosapramine.Experimental
MoxonidineIsocarboxazid may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineIsocarboxazid may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe therapeutic efficacy of Nabilone can be increased when used in combination with Isocarboxazid.Approved, Investigational
NadololIsocarboxazid may increase the hypotensive activities of Nadolol.Approved
NaftopidilIsocarboxazid may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Isocarboxazid.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Isocarboxazid.Investigational
NaphazolineIsocarboxazid may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Isocarboxazid.Approved, Investigational
NateglinideIsocarboxazid may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololIsocarboxazid may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe therapeutic efficacy of Nefazodone can be increased when used in combination with Isocarboxazid.Approved, Withdrawn
NefiracetamThe therapeutic efficacy of Nefiracetam can be increased when used in combination with Isocarboxazid.Investigational
NesiritideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nesiritide.Approved, Investigational
NialamideThe therapeutic efficacy of Nialamide can be increased when used in combination with Isocarboxazid.Withdrawn
NicardipineIsocarboxazid may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Isocarboxazid.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nifedipine.Approved
NiguldipineIsocarboxazid may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineIsocarboxazid may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineIsocarboxazid may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineIsocarboxazid may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe therapeutic efficacy of Nitrazepam can be increased when used in combination with Isocarboxazid.Approved
NitrendipineIsocarboxazid may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nitroglycerin.Approved, Investigational
NitroprussideIsocarboxazid may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nitrous acid.Approved, Investigational
NordazepamThe therapeutic efficacy of Nordazepam can be increased when used in combination with Isocarboxazid.Approved
NorepinephrineIsocarboxazid may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Isocarboxazid.Approved, Illicit
NortriptylineThe therapeutic efficacy of Nortriptyline can be increased when used in combination with Isocarboxazid.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Obinutuzumab.Approved, Investigational
OctamoxinIsocarboxazid may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe therapeutic efficacy of Olanzapine can be increased when used in combination with Isocarboxazid.Approved, Investigational
OlmesartanIsocarboxazid may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Olodaterol.Approved
OmapatrilatIsocarboxazid may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronThe therapeutic efficacy of Ondansetron can be increased when used in combination with Isocarboxazid.Approved
OpipramolThe therapeutic efficacy of Opipramol can be increased when used in combination with Isocarboxazid.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Isocarboxazid.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Orciprenaline.Approved
OsanetantThe therapeutic efficacy of Osanetant can be increased when used in combination with Isocarboxazid.Investigational
OxaprotilineThe therapeutic efficacy of Oxaprotiline can be increased when used in combination with Isocarboxazid.Experimental
OxazepamThe therapeutic efficacy of Oxazepam can be increased when used in combination with Isocarboxazid.Approved
OxiracetamThe therapeutic efficacy of Oxiracetam can be increased when used in combination with Isocarboxazid.Experimental
OxitriptanThe therapeutic efficacy of Oxitriptan can be increased when used in combination with Isocarboxazid.Approved, Investigational, Nutraceutical
OxprenololThe therapeutic efficacy of Oxprenolol can be increased when used in combination with Isocarboxazid.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineIsocarboxazid may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Isocarboxazid.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneThe therapeutic efficacy of Paliperidone can be increased when used in combination with Isocarboxazid.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Isocarboxazid.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Papaverine.Approved, Investigational
PargylineIsocarboxazid may increase the hypertensive activities of Pargyline.Approved
ParoxetineThe therapeutic efficacy of Paroxetine can be increased when used in combination with Isocarboxazid.Approved, Investigational
PenbutololIsocarboxazid may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe therapeutic efficacy of Penfluridol can be increased when used in combination with Isocarboxazid.Experimental
PentamidineIsocarboxazid may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Isocarboxazid.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Isocarboxazid.Approved, Investigational, Vet Approved
PentoliniumIsocarboxazid may increase the hypotensive activities of Pentolinium.Approved
PerazineThe therapeutic efficacy of Perazine can be increased when used in combination with Isocarboxazid.Approved, Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Isocarboxazid.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilIsocarboxazid may increase the hypotensive activities of Perindopril.Approved
PerospironeThe therapeutic efficacy of Perospirone can be increased when used in combination with Isocarboxazid.Approved
PerphenazineThe therapeutic efficacy of Perphenazine can be increased when used in combination with Isocarboxazid.Approved
PethidineIsocarboxazid may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Isocarboxazid is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Isocarboxazid.Experimental
PhencyclidineThe therapeutic efficacy of Phencyclidine can be increased when used in combination with Isocarboxazid.Illicit
PhendimetrazineIsocarboxazid may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzineThe therapeutic efficacy of Phenelzine can be increased when used in combination with Isocarboxazid.Approved
PhenethylamineThe therapeutic efficacy of Phenethylamine can be increased when used in combination with Isocarboxazid.Experimental
PhenibutThe therapeutic efficacy of Phenibut can be increased when used in combination with Isocarboxazid.Experimental
PheniprazineIsocarboxazid may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Isocarboxazid.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Isocarboxazid.Experimental
PhenoxybenzamineIsocarboxazid may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineIsocarboxazid may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineIsocarboxazid may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineIsocarboxazid may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineIsocarboxazid may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Isocarboxazid.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Isocarboxazid.Investigational
PimozideThe therapeutic efficacy of Pimozide can be increased when used in combination with Isocarboxazid.Approved
PinacidilIsocarboxazid may increase the hypotensive activities of Pinacidil.Approved
PindololIsocarboxazid may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneIsocarboxazid may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe therapeutic efficacy of Pipamperone can be increased when used in combination with Isocarboxazid.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Isocarboxazid.Approved, Investigational
PirlindoleThe therapeutic efficacy of Pirlindole can be increased when used in combination with Isocarboxazid.Approved
PivhydrazineIsocarboxazid may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenIsocarboxazid may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorIsocarboxazid may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideIsocarboxazid may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pramipexole.Approved, Investigational
PramlintideIsocarboxazid may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazepamThe therapeutic efficacy of Prazepam can be increased when used in combination with Isocarboxazid.Approved, Illicit
PrazosinIsocarboxazid may increase the hypotensive activities of Prazosin.Approved
PregabalinThe therapeutic efficacy of Pregabalin can be increased when used in combination with Isocarboxazid.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Isocarboxazid.Approved, Vet Approved
ProcaineIsocarboxazid may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineIsocarboxazid may increase the hypertensive activities of Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Procaterol.Approved, Investigational
ProchlorperazineThe therapeutic efficacy of Prochlorperazine can be increased when used in combination with Isocarboxazid.Approved, Vet Approved
ProgabideThe therapeutic efficacy of Progabide can be increased when used in combination with Isocarboxazid.Approved, Investigational
PromazineThe therapeutic efficacy of Promazine can be increased when used in combination with Isocarboxazid.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Isocarboxazid.Approved, Investigational
PropericiazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Propericiazine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Propofol.Approved, Investigational, Vet Approved
PropranololIsocarboxazid may increase the hypotensive activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Prothipendyl.Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Protokylol.Approved, Vet Approved
ProtriptylineThe therapeutic efficacy of Protriptyline can be increased when used in combination with Isocarboxazid.Approved
PseudoephedrineIsocarboxazid may increase the hypertensive activities of Pseudoephedrine.Approved
PsilocybineThe therapeutic efficacy of Psilocybine can be increased when used in combination with Isocarboxazid.Investigational
QuetiapineThe therapeutic efficacy of Quetiapine can be increased when used in combination with Isocarboxazid.Approved
QuinaprilIsocarboxazid may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineIsocarboxazid may increase the hypoglycemic activities of Quinine.Approved
RacepinephrineIsocarboxazid may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe therapeutic efficacy of Raclopride can be increased when used in combination with Isocarboxazid.Investigational
RamiprilIsocarboxazid may increase the hypotensive activities of Ramipril.Approved
RasagilineIsocarboxazid may increase the hypertensive activities of Rasagiline.Approved
ReboxetineThe therapeutic efficacy of Reboxetine can be increased when used in combination with Isocarboxazid.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Isocarboxazid.Approved
RemikirenIsocarboxazid may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe therapeutic efficacy of Remoxipride can be increased when used in combination with Isocarboxazid.Approved, Withdrawn
RepaglinideIsocarboxazid may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineIsocarboxazid may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Reserpine.Approved, Investigational
RilmenidineIsocarboxazid may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatIsocarboxazid may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe therapeutic efficacy of Risperidone can be increased when used in combination with Isocarboxazid.Approved, Investigational
RitanserinThe therapeutic efficacy of Ritanserin can be increased when used in combination with Isocarboxazid.Investigational
RitobegronIsocarboxazid may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ritodrine.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Isocarboxazid.Approved
RolipramThe therapeutic efficacy of Rolipram can be increased when used in combination with Isocarboxazid.Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Isocarboxazid.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ropivacaine.Approved
RosiglitazoneIsocarboxazid may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Isocarboxazid.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sacubitril.Approved
SafrazineIsocarboxazid may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salmeterol.Approved
SaprisartanIsocarboxazid may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinIsocarboxazid may increase the hypoglycemic activities of Saxagliptin.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Isocarboxazid.Approved, Vet Approved
SelegilineSelegiline may increase the hypertensive activities of Isocarboxazid.Approved, Investigational, Vet Approved
SelexipagIsocarboxazid may increase the hypotensive activities of Selexipag.Approved
SertindoleThe therapeutic efficacy of Sertindole can be increased when used in combination with Isocarboxazid.Approved, Investigational, Withdrawn
SertralineThe therapeutic efficacy of Sertraline can be increased when used in combination with Isocarboxazid.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sevoflurane.Approved, Vet Approved
SibutramineThe therapeutic efficacy of Sibutramine can be increased when used in combination with Isocarboxazid.Approved, Illicit, Investigational, Withdrawn
SitagliptinIsocarboxazid may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanIsocarboxazid may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sotalol.Approved
SpiraprilIsocarboxazid may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isocarboxazid.Approved, Investigational
SulfadiazineIsocarboxazid may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleIsocarboxazid may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleIsocarboxazid may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be increased when used in combination with Isocarboxazid.Approved, Investigational
SultoprideThe therapeutic efficacy of Sultopride can be increased when used in combination with Isocarboxazid.Experimental
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Isocarboxazid.Approved, Investigational
SunitinibIsocarboxazid may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololIsocarboxazid may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tamsulosin.Approved, Investigational
TandospironeThe therapeutic efficacy of Tandospirone can be increased when used in combination with Isocarboxazid.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Isocarboxazid.Approved
Tedizolid phosphateTedizolid Phosphate may increase the serotonergic activities of Isocarboxazid.Approved
TelmisartanIsocarboxazid may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe therapeutic efficacy of Temazepam can be increased when used in combination with Isocarboxazid.Approved, Investigational
TemocaprilIsocarboxazid may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terbutaline.Approved
TerlipressinIsocarboxazid may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tetrabenazine.Approved, Investigational
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Isocarboxazid.Investigational
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be increased when used in combination with Isocarboxazid.Investigational
TetryzolineIsocarboxazid may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineIsocarboxazid may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Isocarboxazid.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Isocarboxazid.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thioproperazine.Approved
ThioridazineThe therapeutic efficacy of Thioridazine can be increased when used in combination with Isocarboxazid.Approved, Withdrawn
ThiothixeneThe therapeutic efficacy of Thiothixene can be increased when used in combination with Isocarboxazid.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Isocarboxazid.Approved, Investigational
TiaprideThe therapeutic efficacy of Tiapride can be increased when used in combination with Isocarboxazid.Approved, Investigational
TiboloneIsocarboxazid may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenIsocarboxazid may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Isocarboxazid.Experimental
TimololIsocarboxazid may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tizanidine.Approved, Investigational
TofisopamThe therapeutic efficacy of Tofisopam can be increased when used in combination with Isocarboxazid.Approved
TolazamideIsocarboxazid may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineIsocarboxazid may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideIsocarboxazid may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isocarboxazid.Approved, Withdrawn
TolonidineIsocarboxazid may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneThe therapeutic efficacy of Toloxatone can be increased when used in combination with Isocarboxazid.Approved
TorasemideIsocarboxazid may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Isocarboxazid.Approved, Investigational
TrandolaprilIsocarboxazid may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineThe therapeutic efficacy of Tranylcypromine can be increased when used in combination with Isocarboxazid.Approved, Investigational
TravoprostIsocarboxazid may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe therapeutic efficacy of Trazodone can be increased when used in combination with Isocarboxazid.Approved, Investigational
TreprostinilIsocarboxazid may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Triamterene.Approved
TriazolamThe therapeutic efficacy of Triazolam can be increased when used in combination with Isocarboxazid.Approved, Investigational
TrichlormethiazideIsocarboxazid may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe therapeutic efficacy of Trifluoperazine can be increased when used in combination with Isocarboxazid.Approved, Investigational
TrifluperidolThe therapeutic efficacy of Trifluperidol can be increased when used in combination with Isocarboxazid.Experimental
TriflupromazineThe therapeutic efficacy of Triflupromazine can be increased when used in combination with Isocarboxazid.Approved, Vet Approved
TrimazosinIsocarboxazid may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanIsocarboxazid may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineThe therapeutic efficacy of Trimipramine can be increased when used in combination with Isocarboxazid.Approved
TropisetronTropisetron may increase the serotonergic activities of Isocarboxazid.Approved, Investigational
UnoprostoneIsocarboxazid may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilIsocarboxazid may increase the hypotensive activities of Urapidil.Investigational
Valproic AcidThe therapeutic efficacy of Valproic Acid can be increased when used in combination with Isocarboxazid.Approved, Investigational
ValsartanIsocarboxazid may increase the hypotensive activities of Valsartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Isocarboxazid.Approved
VenlafaxineThe therapeutic efficacy of Venlafaxine can be increased when used in combination with Isocarboxazid.Approved
VeraliprideThe therapeutic efficacy of Veralipride can be increased when used in combination with Isocarboxazid.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Verapamil.Approved
VilanterolThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Vilanterol.Approved
VilazodoneThe therapeutic efficacy of Vilazodone can be increased when used in combination with Isocarboxazid.Approved
ViloxazineThe therapeutic efficacy of Viloxazine can be increased when used in combination with Isocarboxazid.Approved, Investigational, Withdrawn
VincamineIsocarboxazid may increase the hypotensive activities of Vincamine.Experimental
VinpocetineIsocarboxazid may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe therapeutic efficacy of Vortioxetine can be increased when used in combination with Isocarboxazid.Approved, Investigational
XipamideIsocarboxazid may increase the hypotensive activities of Xipamide.Experimental
XylometazolineIsocarboxazid may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZimelidineIsocarboxazid may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe therapeutic efficacy of Ziprasidone can be increased when used in combination with Isocarboxazid.Approved
ZofenoprilIsocarboxazid may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe therapeutic efficacy of Zolazepam can be increased when used in combination with Isocarboxazid.Vet Approved
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Isocarboxazid.Approved, Investigational
ZotepineThe therapeutic efficacy of Zotepine can be increased when used in combination with Isocarboxazid.Approved, Investigational, Withdrawn
ZuclopenthixolThe therapeutic efficacy of Zuclopenthixol can be increased when used in combination with Isocarboxazid.Approved, Investigational
Food Interactions
  • Take without regard to meals, avoid tyramine, caffeine and alcohol.

References

General References
  1. Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE: A trial of isocarboxazid in the treatment of bulimia nervosa. J Clin Psychopharmacol. 1988 Dec;8(6):391-6. [PubMed:3069879]
  2. BARBER JM, MURPHY FM, CHEESEMAN EA: A clinical trial of isocarboxazid ('marplan') in angina pectoris. Br Heart J. 1962 Mar;24:192-4. [PubMed:13864836]
  3. SCHWARTZ MA: The metabolism of isocarboxazid (marplan) in the rat. J Pharmacol Exp Ther. 1960 Oct;130:157-65. [PubMed:13749111]
  4. Institute of Medicine (US) Council on Health Care Technology (1994). Medical Technology Assessment Directory (2nd ed.). American Medical Association Drug Evaluation.
  5. Owens D. (2010). Companion to psychiatric studies (8th ed.). Elsevier.
  6. Schatzberg A. and Nemeroff C. (2009). The american psychiatric publishing textbook of psychopharmacology (4th ed.). American Psychiatric Publishing Inc..
  7. Validus pharma news [Link]
  8. National Institute of Mental Health [Link]
External Links
Human Metabolome Database
HMDB0015377
KEGG Drug
D02580
PubChem Compound
3759
PubChem Substance
46505330
ChemSpider
3628
BindingDB
163692
ChEBI
93635
ChEMBL
CHEMBL1201168
Therapeutic Targets Database
DAP000577
PharmGKB
PA450101
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Isocarboxazid
ATC Codes
N06AF01 — Isocarboxazid
FDA label
Download (56.5 KB)
MSDS
Download (186 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceAlzheimer's Disease (AD) / Healthy Volunteers / Molecular Imaging1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Oxford Pharmaceutical Services Inc.
  • Validus Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral10 mg/1
Prices
Unit descriptionCostUnit
Marplan 10 mg tablet3.45USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)105-106 °C'MSDS'
boiling point (°C)394.5ºC at 760 mmHg'MSDS'
water solubilityVery slightly soluble in hot water'MSDS'
logP1.49'MSDS'
pKa10.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.224 mg/mLALOGPS
logP1.19ALOGPS
logP1.43ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)12.02ChemAxon
pKa (Strongest Basic)3.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.16 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity74.78 m3·mol-1ChemAxon
Polarizability24.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9783
Caco-2 permeable-0.5531
P-glycoprotein substrateNon-substrate0.6987
P-glycoprotein inhibitor INon-inhibitor0.9138
P-glycoprotein inhibitor IINon-inhibitor0.9716
Renal organic cation transporterNon-inhibitor0.8247
CYP450 2C9 substrateNon-substrate0.8471
CYP450 2D6 substrateNon-substrate0.8141
CYP450 3A4 substrateNon-substrate0.6057
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8885
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8518
Ames testAMES toxic0.5973
CarcinogenicityCarcinogens 0.5
BiodegradationNot ready biodegradable0.9227
Rat acute toxicity2.9486 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9209
hERG inhibition (predictor II)Non-inhibitor0.9069
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0006-9600000000-952a7c1093fe532d1df3
Mass Spectrum (Electron Ionization)MSsplash10-0006-9500000000-6ab30f52fc69889b3fa2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-9210100010-78b2f412502a142509e6

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Isoxazoles / Heteroaromatic compounds / Carboxylic acid hydrazides / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Monocyclic benzene moiety / Azole / Isoxazole / Heteroaromatic compound / Carboxylic acid hydrazide / Carboxylic acid derivative / Organoheterocyclic compound / Azacycle / Oxacycle / Organooxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Thase ME, Trivedi MH, Rush AJ: MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219. [PubMed:7612154]
  3. Kettler R, Da Prada M, Burkard WP: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl. 1990;360:101-2. [PubMed:2248058]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Mason ST: Chronic administration of type A monoamine oxidase inhibitors increases duration of thiopentone anaesthesia in the rat. Physiol Behav. 1985 Aug;35(2):201-3. [PubMed:4070383]
  2. Kettler R, Da Prada M, Burkard WP: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl. 1990;360:101-2. [PubMed:2248058]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:34